Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

inhaled BMD003(CFTR mRNA)

Phase 1RNA therapy

PPeking Union Medical College Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic Fibrosis (CF)Active, not recruiting

Cystic Fibrosis (CF)Phase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Cystic Fibrosis (CF)

NCT06963008

Clinical

Trials by Indication[1]

Cystic Fibrosis (CF)1 trial

A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Adult Patients With Cystic Fibrosis

Active, not recruiting·PPeking Union Medical College Hospital·Phase 1·NCT06963008·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for inhaled BMD003(CFTR mRNA). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — inhaled BMD003(CFTR mRNA) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for inhaled BMD003(CFTR mRNA). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 1[1]
Company: PPeking Union Medical College Hospital

Related News